"だいどうクリニックは社会医療法人宏潤会が運営する診療所です。外来は37の診療科とさまざまな専門外来を設置。健診や予防接種センター、隣接する大同病院との連携により、地域の中核的診療機関として質の高い医療を提供しています。"

During the past decade, Koujunkai Daido Clinic conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 6 clinical trials were completed, i.e. on average, 26.1% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 5 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Koujunkai Daido Clinic" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Pfizer" with 4 trials sponsored, "Arena Pharmaceuticals" with 2 trials sponsored, "Celgene" with 2 trials sponsored and "Gilead Sciences" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Koujunkai Daido Clinic" #1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Galapagos NV" with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator and "Nektar Therapeutics" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Koujunkai Daido Clinic" are "Ulcerative Colitis" (3 trials), "Crohn's Disease" (2 trials), "Eosinophilic Esophagitis" (2 trials), "Psoriatic Arthritis" (2 trials) and "Alzheimer Disease" (1 trials). Many other conditions were trialed in "Koujunkai Daido Clinic" in a lesser frequency.

Most popular intervention types in "Koujunkai Daido Clinic" are "Drug" (20 trials), "Biological" (3 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Etrasimod" (4 trials), "CC-93538" (2 trials), "Filgotinib" (2 trials) and "Placebo to match filgotinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Koujunkai Daido Clinic" are 23 trials for "All" genders.

Currently, there are NaN active trials in "Koujunkai Daido Clinic". undefined are not yet recruiting, 10 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Koujunkai Daido Clinic, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Koujunkai Daido Clinic, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 19 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".